You are here: Industry Insights > B-Cell

News List

Cellectar Receives FTD for Diffuse Large B-Cell Lymphoma Treatment contractpharma
July 10, 2019
Drug conjugate, CL131, delivers cytotoxic radiation directly and selectively to cancer cells.
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma worldpharmanews
June 20, 2019
FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma.
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting drugs
June 19, 2019
Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting.
Chemoimmunotherapy Regimen Approved to Treat DLBCL drugs
June 11, 2019
Chemoimmunotherapy Regimen Approved to Treat DLBCL.
Cellectar Gains FDA Fast Track for CLR 131 in MM contractpharma
May 16, 2019
CLR 131 is being evaluated in a Phase II study in patients with relapsed or refractory multiple myeloma and other select B-Cell lymphomas.
AbbVie, J&J’s Imbruvica fails to target in B-Cell lymphoma trial pharmatimes
July 16, 2018
AbbVie and Johnson & Johnson’s Imbruvica has failed to meet its key target in a late stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma.